Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Insulin Modulation of fMRI Connectivity in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02982551
Recruitment Status : Withdrawn (Principal Investigator Departed University)
First Posted : December 5, 2016
Last Update Posted : December 4, 2017
Sponsor:
Information provided by (Responsible Party):
John Patrick Ryan, University of Pittsburgh

Brief Summary:
This study evaluates the effects of changing insulin levels on brain activity. Participants will complete functional magnetic resonance imaging (fMRI) scans during fasting conditions, then during an insulin infusion.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Insulin Other: Taste Task Other: Magnetic Resonance Imaging Drug: Dextrose Early Phase 1

Detailed Description:

Insulin is a hormone released by the pancreas in response to increases in glucose levels that result from food intake. In addition to stimulating glucose uptake in the periphery, insulin signals the central nervous system to induce satiety and inhibit feeding behavior.

To begin to identify the specific effects of circulating insulin on brain networks, the current study will recruit healthy participants who will undergo two functional magnetic resonance imaging scans. One scan will be performed in the fasted state, and the alternate scan will be conducted during an isoglycemic hyperinsulinemic clamp.

This project will allow us to identify the specific effects of circulating insulin on brain reactivity to palatable food.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Insulin Modulation of fMRI Connectivity and Food Reward
Actual Study Start Date : January 1, 2016
Estimated Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Hyperinsulinemic Clamp
Participants will complete two MRI scans approximately one hour apart - one under baseline conditions and the second during an insulin infusion. Each scan will include data collected during rest, and a taste task. The taste task involves receiving milkshake or a tasteless solution. After the first scan, an isoglycemic-hyperinsulinemic clamp will be implemented. An IV will be placed in the antecubital vein of of arm for infusion of insulin and dextrose. HumuLIN®-R regular insulin will be infused at 40 mU/m2/min. A second IV will be inserted in the back of the hand on the opposite arm to allow for frequent sampling of blood glucose levels. Dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline value. The study team will monitor blood glucose levels and adjust dextrose infusions as necessary. Thirty minutes after starting the insulin infusion, participants will be moved back into the bore of the MRI scanner for the repeat scans.
Drug: Insulin
Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity
Other Name: HumuLIN®-R

Other: Taste Task
Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.

Other: Magnetic Resonance Imaging
Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.

Drug: Dextrose
During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.




Primary Outcome Measures :
  1. fMRI BOLD Response in Brain [ Time Frame: During Taste Task in fMRI Scanner. Task Duration is approximately 14 minutes. ]
    The investigators will monitor the blood oxygen level dependent response using fMRI and compare activation during "taste" trials vs. "no taste" trials.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 30 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body mass index between 18 and 24
  • HOMA-IR < 1.55 (homeostatic model assessment of insulin resistance - ((glucose x insulin) / 405)).

Exclusion Criteria:

  • Current or lifetime history of any cardiovascular disease or surgery (including hypertension, stroke, myocardial infarction, congestive heart failure, atrial or ventricular arrhythmias, coronary bypass, carotid artery, or peripheral vascular surgery)
  • Current or lifetime history of cancer, a chronic kidney or liver condition, type I or II diabetes, or any pulmonary or respiratory disease
  • Current or lifetime diagnoses of any substance abuse
  • Positive urine drug screen
  • Current or lifetime use of glucocorticoid medications for >1 month
  • A previous cerebrovascular accident or trauma involving loss of consciousness
  • Previous neurosurgery or history of a neurological condition
  • Pregnancy (females)
  • Claustrophobia
  • Ferrous metallic implants or any surgically placed medical device not cleared for safety at 3Tesla MRI strength
  • Peripheral vascular disease
  • Liver, kidney, or active blood disease
  • Peripheral neuropathy
  • Anemia (hematocrit <34%)
  • Inability and/or willingness to comply with the protocol as written
  • Fasting glucose > 126 mg/dL
  • Currently taking blood thinners such as coumadin, Lovenox, etc.
  • Currently taking any medications that can alter glucose homeostasis (steroids, glucocorticoids, nicotinic acid)
  • Current use of any psychotropic medications (SSRI, SNRI, etc.)
  • Currently taking thiazolidinediones or insulin
  • Currently use of statins or anti-hypertensive medications
  • Use of medications related to HIV that can affect insulin sensitivity. We will NOT specifically test for HIV serostatus.
  • Females currently on hormone replacement therapy (HRT) less than 6 months
  • Participants will be instructed to abstain from eating, drinking (other than water), smoking and exercise for the 12 hours prior to each study visit.
  • Being left handed
  • Body mass index above 24 or below 18
  • Milk allergy / lactose intolerance
  • Polycystic ovary syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02982551


Locations
Layout table for location information
United States, Pennsylvania
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Investigators
Layout table for investigator information
Principal Investigator: John P Ryan, PhD University of Pittsburgh

Layout table for additonal information
Responsible Party: John Patrick Ryan, PhD, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT02982551     History of Changes
Other Study ID Numbers: PRO15040502
First Posted: December 5, 2016    Key Record Dates
Last Update Posted: December 4, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs